Canaccord Genuity analyst Tania Armstrong-Whitworth assigned a Buy rating on Knight Therapeutics (KHTRF – Research Report) yesterday and set a price target of C$7.00. Tania Armstrong-Whitworth’s Buy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results